ir.catabasis.com ir.catabasis.com

ir.catabasis.com

Catabasis - Investors - Investor Overview

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform. Enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.

http://ir.catabasis.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.CATABASIS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

March

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.9 out of 5 with 8 reviews
5 star
4
4 star
1
3 star
2
2 star
0
1 star
1

Hey there! Start your review of ir.catabasis.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

2.4 seconds

FAVICON PREVIEW

  • ir.catabasis.com

    16x16

  • ir.catabasis.com

    32x32

  • ir.catabasis.com

    64x64

  • ir.catabasis.com

    128x128

CONTACTS AT IR.CATABASIS.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Catabasis - Investors - Investor Overview | ir.catabasis.com Reviews
<META>
DESCRIPTION
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform. Enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.
<META>
KEYWORDS
1 toggle navigation
2 clinical trials
3 edasalonexent movedmd trial
4 news and updates
5 for further information
6 our technology
7 our pipeline
8 catabasis publications and
9 scientific presentations
10 references
CONTENT
Page content here
KEYWORDS ON
PAGE
toggle navigation,clinical trials,edasalonexent movedmd trial,news and updates,for further information,our technology,our pipeline,catabasis publications and,scientific presentations,references,investor overview,press releases,events and presentations
POWERED BY
ASP.NET
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Catabasis - Investors - Investor Overview | ir.catabasis.com Reviews

https://ir.catabasis.com

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform. Enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.

LINKS TO THIS WEBSITE

catabasis.com catabasis.com

Catabasis

http://www.catabasis.com/careers.php

Catabasis is a dynamic biotechnology company utilizing its proprietary SMART (Safely Metabolized And Targeted) linker technology to develop a robust pipeline of products for the treatment of inflammatory, immunological, and metabolic diseases. If you want to make a difference in patients' lives by discovering and developing important new breakthrough therapies, Catabasis may be the place for you. Catabasis is proud to be an Equal Opportunity Employer.

catabasis.com catabasis.com

Catabasis

http://www.catabasis.com/clinical-trials-cat-1004-movedmd.php

Updated July 11, 2016. The information provided here is for parents and guardians of boys with Duchenne muscular dystrophy (DMD). Edasalonexent (CAT-1004) is an investigational drug that has not been approved by the US Food and Drug Administration. The content is intended for a US audience only. A personal note from Dr. Joanne Donovan, MD, PhD, Chief Medical Officer at Catabasis:. To learn more about Dr. Donovan: http:/ catabasis.com/about-management.php. What is the MoveDMD Trial? Edasalonexent (CAT-100...

catabasis.com catabasis.com

Catabasis

http://www.catabasis.com/media.php

For media inquiries,. Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights. Catabasis Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference. Catabasis Pharmaceuticals to Report Second Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, August 11. Catabasis Pharmaceuticals Names Joseph Johnston VP, Regulatory Affairs. Catabasis Pharmaceuticals Announces Top-Line Phase 2a Results for CAT-2054. Catabasis Pharmace...

catabasis.com catabasis.com

Catabasis

http://www.catabasis.com/sitemap.php

catabasis.com catabasis.com

Catabasis

http://www.catabasis.com/about.php

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform. Enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.

catabasis.com catabasis.com

Catabasis

http://www.catabasis.com/index.php

Learn More About Us. At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our. SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform. Enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.

catabasis.com catabasis.com

Catabasis

http://www.catabasis.com/scitech.php

Our scientific approach is to leverage the growing body of knowledge associated with disease pathways and to rationally design orally bioavailable product candidates that simultaneously interact with multiple biological targets within one or more related disease pathways. Our SMART Linker Technology Platform. Potential Benefits of our SMART Linker Technology Platform. Enhance activity on disease pathways through modulation of multiple biological targets.

UPGRADE TO PREMIUM TO VIEW 8 MORE

TOTAL LINKS TO THIS WEBSITE

15

OTHER SITES

ir.cas2.lehigh.edu ir.cas2.lehigh.edu

International Relations

Come to Know World Politics. Lehigh is among the very few major universities in the United States with a separate Department of International Relations (IR). Secretary-General Ban Ki-moon (at lectern) delivers remarks at the unveiling ceremony of The Ark of Return (left), the Permanent Memorial to honour the Victims of Slavery and the Transatlantic Slave Trade. Get Real World Experience. Examine the Political Dimensions of Trade, Finance, and Development. Welcome to the IR Department. Dinissa Duvanova, A...

ir.cascadianrx.com ir.cascadianrx.com

Overview - Cascadian Therapeutics

Annual Reports and Proxy. We are committed to serving the best interests of our shareholders. If you require assistance or have questions regarding the key shareholder information and financial reports available here please contact. 007 ( 1.54%). 4:00 PM ET on Jan 13, 2017. Delayed at least 20 minutes. Jan 5, 2017. Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress. Jan 4, 2017. View all recent releases ». December 13, 2016. October 10, 2016. June 5, 2016.

ir.casella.com ir.casella.com

Investor Relations | Casella Waste System

Casella Waste Systems, Inc. is an integrated regional solid waste services company that provides collection, transfer, disposal, recycling and resource management services to residential, industrial and commercial customers, primarily throughout the eastern United States. Founded in Rutland, Vermont in 1975 with a single truck, Casella has grown by anticipating and meeting changing cultural and public policy expectations about how our environment and natural resources are managed. Mar 27, 2018.

ir.cassinfo.com ir.cassinfo.com

Cass Information Systems | Investor Relations | Overview

PayCargo Selects Cass Information Systems to Provide B-to-B Payment. Cass Information Systems, Inc. Reports 2nd Quarter 2015 Earnings. Cass Information Systems, Inc. Elects Eric H. Brunngraber Chairman of the Board. Record of Continuous Pay Outs Reaches Year 81 as Cass Information Systems, Inc. Declares $0.21 per Share Dividend for Second Quarter of 2015. Cass Information Systems, Inc. College Station, TX 77842-3170. St Louis, MO 63102. 7700 Forsyth Blvd., Suite 1800. St Louis, MO 63105. 160; 0.39.

ir.castletam.com ir.castletam.com

Castle Tam Hostel-Persian - Castle Tam - Home

1582;انه. 1583;رباره ما. 1582;دمات. 1606;رخ و رزرو. 1580;هت. 1711;الری. 1593;کس. 1601;یلم. 1705;ار می خواهم ؟ 1578;ماس. 1711;شت و گذار. 1587;والات. 1587;والات درمورد هتل. 1705;ستاریکا، سوالات درمورد. 1576;رنامه اتوبوس. 1582;وابگاه قلعه تام خوش آمدید. 1605;ا هستیم در:. 1578;ماس با ما. View Castle Tam, San Pedro, Costa Rica. In a larger map.

ir.catabasis.com ir.catabasis.com

Catabasis - Investors - Investor Overview

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform. Enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.

ir.catalystpharma.com ir.catalystpharma.com

Catalyst Pharmaceuticals, Inc. - Investor Relations

Annual Reports and Proxy Statement. 4:00 PM ET on 03/29/18. Annual Reports and Proxy Statement. View all ». Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome. Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update. View all ». 03/14/18 at 5:00 PM ET. Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast.

ir.cavotec.com ir.cavotec.com

Investor Relations | Cavotec SA

Service for Ports and Maritime. Underground Mining and Tunnelling. Energy, Processing and Transportation. Service for Industry and Mining. Service for Oil and Gas. Board, Group CEO and EMT Members. Board, Group CEO and EMT Members. Welcome to Cavotecs Investor Relations home page. On these pages you will find detailed reports, figures and other materials relating to the performance of the Cavotec share, the Groups corporate governance and Cavotec as a whole. Engelska är koncernens arbetsspråk&...

ir.cboe.com ir.cboe.com

Investor Relations

Quotes and Data Main. Free Real-Time Stock Quotes. LiveOptions Streaming Real-Time Quotes. Cboe Global Markets Monthly Volume and RPC Reports. Cboe Data Services Real-Time Service. Cboe LiveVol Options Analytics. Cboe Daily Market Statistics. Stock Index Options - SPX-RUT-MSCI-FTSE. Options on Single Stocks and Exchange Traded Products. End-of-Month and Quarterly Options. Contract Specs and Trading Hours. Cboe Daily Market Statistics. S&P Daily Strategy Reports. Strategy and Education Videos. Cboe offers...

ir.cbre.com ir.cbre.com

CBRE: Investor Relations - Investor Relations

CBRE is the premier global provider of integrated services to commercial real estate investors and occupiers. Webcasts, Presentations and Transcripts. OTHER PRESENTATIONS and TRANSCRIPTS. Q2 2015 Webcast Slides. Q2 2015 Earnings Conference Call Transcript. June 2015 Investor Presentation. Q1 2015 Webcast Slides. Q1 2015 Earnings Conference Call Transcript. GWS Acquisition Call Transcript. GWS Acquisition Presentation March 2015. Q4 2014 Webcast Slides. Q4 2014 Earnings Conference Call Transcript.

ir.cc.sapmed.ac.jp ir.cc.sapmed.ac.jp

ikor: ホーム

このサービスは、平成14年度から実施しており、病院誌等、一般の商業ルートでは販売されず、入手しづらい資料を総称し、図書館専門用語では 灰色文献 Grey literature と呼びますが、それらの資料を電子化し、検索機能を付与して公開してきました。 その後、サービスの充実を図るために、国立情報学研究所 NII の 次世代学術コンテンツ基盤共同構築事業 学術機関リポジトリ構築連携支援事業平成20-21年度委託事業 以下、委託事業という の採択を受け、平成20年度に 学術機関リポジトリ. 電子化による公開を希望する医療機関等 以下、 医療機関等 と略す は対象誌に収載されている 記事等について執筆者本人より著作権許諾を受諾する。 註 PDFとはAdobe社が開発した電子出版形式で Portable Document Format の略。 北海道医療機関等発行誌 機関名で A- Z、あ行 わ行 に登録. TEL 011-611-2111 FAX011-642-7030 E-mail icccj@sapmed.ac.jp.